Deferasirox is effective in reducing serum ferritin and LIC across a range of transfusion-dependent anemias. Other anemias include AA (n = 5), α-thalassemia (n = 3), sideroblastic anemia (n = 3), myelofibrosis (n = 2), pure red cell aplasia (n = 2), pyruvate kinase deficiency (n = 2), autoimmune hemolytic anemia (n = 1), Fanconi’s anemia (n = 1), hereditary sideroblastic anemia (n = 1), erythropenia (n = 1), and unspecified anemia (n = 1). DW = Dry weight.